Literature DB >> 16098414

Can we estimate the 'social' value of a QALY? Four core issues to resolve.

Richard D Smith1, Jeff Richardson.   

Abstract

There is growing interest in estimating the 'societal' willingness to pay (WTP) for a quality adjusted life year (QALY) to help public health system decision-makers determine whether a health care programme should/not be undertaken. However, there is a lack of clarity in this debate concerning four core issues: (i) is 'social' WTP simply the sum of 'individual' WTP; (ii) will 'individual' WTP map directly into 'social' WTP; (iii) is 'personal' income the appropriate budget constraint; (iv) should WTP be adjusted for ability to pay? This paper outlines the relevance and importance of each of these issues in the hope of encouraging a wider debate on the core issues that empirical studies will have to explore to discover whether such a value may be obtained.

Keywords:  Health Care and Public Health

Mesh:

Year:  2005        PMID: 16098414     DOI: 10.1016/j.healthpol.2004.12.009

Source DB:  PubMed          Journal:  Health Policy        ISSN: 0168-8510            Impact factor:   2.980


  9 in total

Review 1.  A 'league table' of contingent valuation results for pharmaceutical interventions: a hard pill to swallow?

Authors:  Tracey H Sach; Richard D Smith; David K Whynes
Journal:  Pharmacoeconomics       Date:  2007       Impact factor: 4.981

2.  The new myth: the social value of the QALY.

Authors:  Werner Brouwer; Job van Exel; Rachel Baker; Cam Donaldson
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

Review 3.  The NICE cost-effectiveness threshold: what it is and what that means.

Authors:  Christopher McCabe; Karl Claxton; Anthony J Culyer
Journal:  Pharmacoeconomics       Date:  2008       Impact factor: 4.981

4.  Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines.

Authors:  A T Newall; M Jit; R Hutubessy
Journal:  Pharmacoeconomics       Date:  2014-06       Impact factor: 4.981

5.  Willingness to pay for a quality-adjusted life year: a systematic review with meta-regression.

Authors:  Christian R C Kouakou; Thomas G Poder
Journal:  Eur J Health Econ       Date:  2021-08-21

6.  Willingness to pay for a QALY based on community member and patient preferences for temporary health states associated with herpes zoster.

Authors:  Tracy A Lieu; G Thomas Ray; Ismael R Ortega-Sanchez; Ken Kleinman; Donna Rusinak; Lisa A Prosser
Journal:  Pharmacoeconomics       Date:  2009       Impact factor: 4.981

7.  Individual Cognitive Stimulation Therapy for dementia (iCST): study protocol for a randomized controlled trial.

Authors:  Martin Orrell; Lauren A Yates; Alistair Burns; Ian Russell; Robert T Woods; Zoe Hoare; Esme Moniz-Cook; Catherine Henderson; Martin Knapp; Aimee Spector; Vasiliki Orgeta
Journal:  Trials       Date:  2012-09-22       Impact factor: 2.279

8.  Sample Size Estimation for Non-Inferiority Trials: Frequentist Approach versus Decision Theory Approach.

Authors:  A C Bouman; A J ten Cate-Hoek; B L T Ramaekers; M A Joore
Journal:  PLoS One       Date:  2015-06-15       Impact factor: 3.240

9.  Estimating the willingness to pay for a quality-adjusted life year in Thailand: does the context of health gain matter?

Authors:  Montarat Thavorncharoensap; Yot Teerawattananon; Sirin Natanant; Wantanee Kulpeng; Jomkwan Yothasamut; Pitsaphun Werayingyong
Journal:  Clinicoecon Outcomes Res       Date:  2013-01-09
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.